Skip to main content
logo
Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0300
0.00 (0.00%)
Sep 8, 2026, 2:23 PM EST

Oncotelic Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.25--0.07--
Revenue Growth
------
Gross Profit
0.25--0.07--
Operating Income
-5.52-2.99-0.38-0.56-5.61-9.13
Net Income
247.5249.28-4.52-7.95.09-9.39
Earnings Per Share
0.560.59-0.01-0.020.01-0.03
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.190.090.090.170.240.57
Total Debt
13.8913.9113.0912.5711.268.99
Net Cash (Debt)
-13.71-13.82-13-12.4-11.02-8.42
Net Cash Growth
------
Net Cash Per Share
-0.03-0.03-0.03-0.03-0.02-0.03

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1.52-1.38-0.74-1.32-1.45-4.43
Free Cash Flow
-1.52-1.38-0.74-1.32-1.45-4.43
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%--100.00%--
Operating Margin
-2206.59%---806.96%--
Pretax Margin
143532.19%---11722.95%--
Profit Margin
98998.02%---11290.13%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
0.060.15--3.45-
PS Ratio
57.35--218.13--